Role of Genetic Variants and Gene Expression in the Susceptibility and Severity of COVID-19

키워드

참고문헌 (73)

1. Ki Ho Hong, "Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea", Annals of Laboratory Medicine, 40(5), pp.351~360 (2020), 대한진단검사의학회[DOI]
2. Mitra P, "COVID-19 pandemic in India: what lies ahead", Ind J Clin Biochem, 35, pp.257~259 (2020)
3. Heungsup Sung, "COVID-19 Molecular Testing in Korea: Practical Essentials and Answers From Experts Based on Experiences of Emergency Use Authorization Assays", Annals of Laboratory Medicine, 40(6), pp.439~447 (2020), 대한진단검사의학회[DOI]
4. Mitra P, "Association of comorbidities with coronavirus disease 2019: a review", Ann Natl Acad Med Sci (India), 56, pp.102~111 (2020)
5. "Coronavirus disease (COVID-19) dashboard"[URL]
6. Lingeswaran M, "Inflammation, immunity and immunogenetics in COVID-19: a narrative review", Indian J Clin Biochem, 35, pp.260~273 (2020)
7. Lacoma A, "Impact of host genetics and biological response modifiers on respiratory tract infections", Front Immunol, 10, pp.1013~ (2019)
8. Benetti E, "ACE2gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population", Eur J Hum Genet, pp.1~13 (2020)
9. Chen YY, "Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites", J Clin Pharm Ther, 43, pp.189~195 (2018)
10. Patel SK, "Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes", Am J Hypertens, 25, pp.216~222 (2012)
11. Zhang SF, "Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou", PLoS One, 13, pp.e0191789~ (2018)
12. Hu B, "Bat origin of human coronaviruses", Virol J, 12, pp.221~ (2015)
13. Pyrc K, "The novel human coronaviruses NL63 and HKU1", J Virol, 81, pp.3051~3057 (2007)
14. Devaux CA, "ACE2 receptor polymorphism: susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome", J Microbiol Immunol Infect, 53, pp.425~435 (2020)
15. Ye J, "Molecular pathology in the lungs of severe acute respiratory syndrome patients", Am J Pathol, 170, pp.538~545 (2007)
16. To KF, "Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases", J Pathol, 202, pp.157~163 (2004)
17. Nicholls JM, "Lung pathology of fatal severe acute respiratory syndrome", Lancet, 361, pp.1773~1778 (2003)
18. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
19. Tipnis SR, "A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase", J Biol Chem, 275, pp.33238~33243 (2000)
20. Patel VB, "Role of the ACE2", angiotensin 1–7 axis of the renin-angiotensin system in heart failure, 2016, pp.118, 1313~1326
21. Vickers C, "Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase", J Biol Chem, 277, pp.14838~14843 (2002)
22. Gheblawi M, "Angiotensin converting Enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2", Circ Res, 126, pp.1456~1474 (2020)
23. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
24. Li W, "Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus", Nature, 426, pp.450~454 (2003)
25. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292.e6 (2020)
26. Fu J, "Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19", Mol Biol Rep, 47, pp.4383~4392 (2020)
27. Chen Y, "Structure analysis of the receptor binding of 2019-nCoV", Biochem Biophys Res Commun, 525, pp.135~140 (2020)
28. Zhou P, "A pneumonia outbreak associated with a new coronavirus of probable bat origin", Nature, 579, pp.270~273 (2020)
29. Qiu Y, "Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2", Microbes Infect, 22, pp.221~225 (2020)
30. Li W, "Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2", EMBO J, 24, pp.1634~1643 (2005)
31. Wan Y, "Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus", J Virol, 94, pp.e00127-20~ (2020)
32. Rice GI, "Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study", Hypertension, 48, pp.914~920 (2006)
33. Ciaglia E, "COVID-19 infection and circulating ACE2 levels: protective role in women and children", Front Pediatr, 8, pp.206~ (2020)
34. Mushtaq Hussain, "Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein", Journal of Medical Virology, 92(9), pp.1580~1586 (2020), Wiley[DOI]
35. Xia S, "Inhibition of SARSCoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion", Cell Res, 30, pp.343~355 (2020)
36. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
37. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
38. Chen J, "Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation", Aging Cell, 19, pp.e13168~ (2020)
39. Cao Y, "Comparative genetic analysis of the novel coronavirus (2019-nCoV", SARS-CoV-2) receptor ACE2 in different populations, 2020, pp.6, 11~
40. Zhao Y, "Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2", Am J Respir Crit Care Med, 202, pp.756~759 (2020)
41. Li M, "Expression of the SARS-CoV-2 cell recep-tor gene ACE2 in a wide variety of human tissues", Infect Dis Poverty, 9, pp.45~ (2020)
42. Bénéteau-Burnat B, "Serum angiotensin-converting enzyme in healthy and sarcoidotic children: comparison with the reference interval for adults", Clin Chem, 36, pp.344~346 (1990)
43. Day CW, "A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo", Virology, 395, pp.210~222 (2009)
44. Ghadhanfar E, "The role of ACE2, angiotensin-(1–7) and Mas1 receptor axis in glucocorticoid-induced intrauterine growth restriction", Reprod Biol Endocrinol, 15, pp.97~ (2017)
45. [URL]
46. Lucas JM, "The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis", Cancer Discov, 4, pp.1310~1325 (2014)
47. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280.e8 (2020)
48. Böttcher E, "Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium", J Virol, 80, pp.9896~9898 (2006)
49. Shulla A, "A. transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry", J Virol, 85, pp.873~882 (2011)
50. Watanabe R, "Entry from the cell surface of severe acute respiratory syndrome coronavirus with cleaved S protein as revealed by pseudotype virus bearing cleaved S protein", J Virol, 82, pp.11985~11991 (2008)
51. Belouzard S, "Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites", Proc Natl Acad Sci, 106, pp.5871~5876 (2009)
52. Matsuyama S, "Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2", J Virol, 84, pp.12658~12664 (2010)
53. Kam YW, "Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro", PLoS One, 4, pp.e7870~ (2009)
54. Heurich A, "TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein", J Virol, 88, pp.1293~1307 (2014)
55. Asselta R, "ACE2 and TMPRSS2variants and expression as candidates to sex and country differences in COVID-19 severity in Italy", Aging (Albany NY), 12, pp.10087~10098 (2020)
56. FitzGerald LM, "Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer", BMC Cancer, 8, pp.230~ (2008)
57. Clinckemalie L, "Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element", Mol Endocrinol, 27, pp.2028~2040 (2013)
58. Senapati S, "Assessment of risk conferred by coding and regulatory variations of TMPRSS2and CD26 in susceptibility to SARS-CoV-2 infection in human", J Genet, 99, pp.53~ (2020)
59. Vankadari N, "Emerging WuHan (COVID-19) coronavirus:glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26", Emerg Microbes Infect, 9, pp.601~604 (2020)
60. Beutler B, "Innate immunity: an overview", Mol Immunol, 40, pp.945~959 (2004)
61. Ivashkiv LB, "Regulation of type I interferon responses", Nat Rev Immunol, 14, pp.36~49 (2014)
62. Schneider WM, "Interferon-stimulated genes: a complex web of host defenses", Annu Rev Immunol, 32, pp.513~545 (2014)
63. García-Sastre A, "Type 1 interferons and the virus–host relationship: a lesson in détente", Science, 312, pp.879~882 (2006)
64. Stender JD, "Epigenomic control of the innate immune response", Curr Opin Pharmacol, 13, pp.582~587 (2013)
65. Agalioti T, "Ordered recruitment of chromatin modifying and general transcription factors to the IFN-β promoter", Cell, 103, pp.667~678 (2000)
66. Busslinger M, "Epigenetic control of immunity", Cold Spring Harb Perspect Biol, 6, pp.a019307~ (2014)
67. Smale ST, "Chromatin contributions to the regulation of innate immunity", Annu Rev Immunol, 32, pp.489~511 (2014)
68. Marban C, "Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing", EMBO J, 26, pp.412~423 (2007)
69. Corley MJ, "methylation analysis of the COVID-19 host cell receptor, angiotensin convert enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences", Preprints, pp.2020030295~ (2020)
70. Pinto BGG, "ACE2 Expression is Increased in the Lungs of Patients with Comorbidities Associated with Severe COVID-19", J Infect Dis, 222, pp.556~563 (2020)
71. Sawalha AH, "Epigenetic dysregulation of ACE2and interferonregulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients", Clin Immunol, 215, pp.108410~ (2020)
72. Pfeffer S, "Identification of virus-encoded microRNAs", Science, 304, pp.734~736 (2004)
73. Saçar Demirci MD, "Computational analysis of microRNAmediated interactions in SARS-CoV-2 infection", PeerJ, 8, pp.e9369~ (2020)

관련 논문AI추천